We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Celgene Hit With Expansive Antitrust Suit Over Thalomid

Law360, New York (September 29, 2017, 5:16 PM EDT) -- A health fund hit Celgene Corp. with a proposed class action Thursday in New Jersey federal court over the company's alleged anti-competitive behavior meant to keep its monopoly on the drugs Thalomid...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.